<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>2016 WHO classification of mature lymphoid, histiocytic, and dendritic neoplasms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">2016 WHO classification of mature lymphoid, histiocytic, and dendritic neoplasms</h1>
<div class="graphic"><div class="figure"><div class="ttl">2016 WHO classification of mature lymphoid, histiocytic, and dendritic neoplasms</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Mature B cell neoplasms</td> </tr> <tr> <td class="indent1">Chronic lymphocytic leukemia/small lymphocytic lymphoma</td> </tr> <tr> <td class="indent1">Monoclonal B cell lymphocytosis*</td> </tr> <tr> <td class="indent1">B cell prolymphocytic leukemia</td> </tr> <tr> <td class="indent1">Splenic marginal zone lymphoma</td> </tr> <tr> <td class="indent1">Hairy cell leukemia</td> </tr> <tr> <td class="indent1">Lymphoplasmacytic lymphoma</td> </tr> <tr> <td class="indent2"> <ul> <li>Waldenström macroglobulinemia </li> </ul> </td> </tr> <tr> <td class="indent1">Monoclonal gammopathy of undetermined significance (MGUS), IgM*</td> </tr> <tr> <td class="indent1">µ heavy chain disease</td> </tr> <tr> <td class="indent1">γ heavy chain disease</td> </tr> <tr> <td class="indent1">α heavy chain disease</td> </tr> <tr> <td class="indent1">Monoclonal gammopathy of undetermined significance (MGUS), IgG/A*</td> </tr> <tr> <td class="indent1">Plasma cell myeloma</td> </tr> <tr> <td class="indent1">Solitary plasmacytoma of bone</td> </tr> <tr> <td class="indent1">Extraosseous plasmacytoma</td> </tr> <tr> <td class="indent1">Monoclonal immunoglobulin deposition diseases*</td> </tr> <tr> <td class="indent1">Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</td> </tr> <tr> <td class="indent1">Nodal marginal zone lymphoma</td> </tr> <tr> <td class="indent1">Follicular lymphoma</td> </tr> <tr> <td class="indent2"> <ul> <li>In situ follicular neoplasia* </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Duodenal-type follicular lymphoma* </li> </ul> </td> </tr> <tr> <td class="indent1">Pediatric-type follicular lymphoma*</td> </tr> <tr> <td class="indent1">Primary cutaneous follicle center lymphoma</td> </tr> <tr> <td class="indent1">Mantle cell lymphoma</td> </tr> <tr> <td class="indent2"> <ul> <li>In situ mantle cell neoplasia* </li> </ul> </td> </tr> <tr> <td class="indent1">Diffuse large B cell lymphoma (DLBCL), NOS</td> </tr> <tr> <td class="indent2"> <ul> <li>Germinal center B cell type* </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Activated B cell type* </li> </ul> </td> </tr> <tr> <td class="indent1">T cell/histiocyte-rich large B cell lymphoma</td> </tr> <tr> <td class="indent1">Primary DLBCL of the central nervous system (CNS)</td> </tr> <tr> <td class="indent1">Primary cutaneous DLBCL, leg type</td> </tr> <tr> <td class="indent1">EBV<sup>+</sup> DLBCL, NOS*</td> </tr> <tr> <td class="indent1">DLBCL associated with chronic inflammation</td> </tr> <tr> <td class="indent1">Lymphomatoid granulomatosis</td> </tr> <tr> <td class="indent1">Primary mediastinal (thymic) large B cell lymphoma</td> </tr> <tr> <td class="indent1">Intravascular large B cell lymphoma</td> </tr> <tr> <td class="indent1">ALK<sup>+</sup> large B cell lymphoma</td> </tr> <tr> <td class="indent1">Plasmablastic lymphoma</td> </tr> <tr> <td class="indent1">Primary effusion lymphoma</td> </tr> <tr> <td class="indent1">Burkitt lymphoma</td> </tr> <tr> <td class="indent1">High-grade B cell lymphoma, with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> rearrangements*</td> </tr> <tr> <td class="indent1">High-grade B cell lymphoma, NOS*</td> </tr> <tr class="divider_bottom"> <td class="indent1">B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma</td> </tr> <tr> <td class="subtitle1_single">Mature T and NK neoplasms</td> </tr> <tr> <td class="indent1">T cell prolymphocytic leukemia</td> </tr> <tr> <td class="indent1">T cell large granular lymphocytic leukemia</td> </tr> <tr> <td class="indent1">Aggressive NK cell leukemia</td> </tr> <tr> <td class="indent1">Systemic EBV<sup>+</sup> T cell lymphoma of childhood*</td> </tr> <tr> <td class="indent1">Hydroa vacciniforme-like lymphoproliferative disorder*</td> </tr> <tr> <td class="indent1">Adult T cell leukemia/lymphoma</td> </tr> <tr> <td class="indent1">Extranodal NK/T cell lymphoma, nasal type</td> </tr> <tr> <td class="indent1">Enteropathy-associated T cell lymphoma</td> </tr> <tr> <td class="indent1">Monomorphic epitheliotropic intestinal T cell lymphoma*</td> </tr> <tr> <td class="indent1">Hepatosplenic T cell lymphoma</td> </tr> <tr> <td class="indent1">Subcutaneous panniculitis-like T cell lymphoma</td> </tr> <tr> <td class="indent1">Mycosis fungoides</td> </tr> <tr> <td class="indent1">Sézary syndrome</td> </tr> <tr> <td class="indent1">Primary cutaneous CD30<sup>+</sup> T cell lymphoproliferative disorders</td> </tr> <tr> <td class="indent2"> <ul> <li>Lymphomatoid papulosis </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Primary cutaneous anaplastic large cell lymphoma </li> </ul> </td> </tr> <tr> <td class="indent1">Primary cutaneous γδ T cell lymphoma</td> </tr> <tr> <td class="indent1">Peripheral T cell lymphoma, NOS</td> </tr> <tr> <td class="indent1">Angioimmunoblastic T cell lymphoma</td> </tr> <tr> <td class="indent1">Anaplastic large cell lymphoma, ALK<sup>+</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">Anaplastic large cell lymphoma, ALK<sup>–</sup>*</td> </tr> <tr> <td class="subtitle1_single">Hodgkin lymphoma</td> </tr> <tr> <td class="indent1">Nodular lymphocyte predominant Hodgkin lymphoma</td> </tr> <tr> <td class="indent1">Classical Hodgkin lymphoma</td> </tr> <tr> <td class="indent2"> <ul> <li>Nodular sclerosis classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Lymphocyte-rich classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Mixed cellularity classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent2"> <ul> <li>Lymphocyte-depleted classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Post-transplant lymphoproliferative disorders (PTLD)</td> </tr> <tr> <td class="indent1">Plasmacytic hyperplasia PTLD</td> </tr> <tr> <td class="indent1">Infectious mononucleosis PTLD</td> </tr> <tr> <td class="indent1">Florid follicular hyperplasia PTLD*</td> </tr> <tr> <td class="indent1">Polymorphic PTLD</td> </tr> <tr> <td class="indent1">Monomorphic PTLD (B and T/NK cell types)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Classical Hodgkin lymphoma PTLD</td> </tr> <tr> <td class="subtitle1_single">Histiocytic and dendritic cell neoplasms</td> </tr> <tr> <td class="indent1">Histiocytic sarcoma</td> </tr> <tr> <td class="indent1">Langerhans cell histiocytosis</td> </tr> <tr> <td class="indent1">Langerhans cell sarcoma</td> </tr> <tr> <td class="indent1">Indeterminate dendritic cell tumor</td> </tr> <tr> <td class="indent1">Interdigitating dendritic cell sarcoma</td> </tr> <tr> <td class="indent1">Follicular dendritic cell sarcoma</td> </tr> <tr> <td class="indent1">Fibroblastic reticular cell tumor</td> </tr> <tr> <td class="indent1">Disseminated juvenile xanthogranuloma</td> </tr> <tr> <td class="indent1">Erdheim-Chester disease*</td> </tr> </tbody></table></div><div class="graphic_lgnd">Provisional entities are not listed.</div><div class="graphic_footnotes">* Changes from the 2008 classification.</div><div class="graphic_reference">Modified with permission of the American Society of Hematology, from Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375. Copyright © 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id="graphicVersion">Graphic 110240 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
